Cargando…
Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma
BACKGROUND: Sunitinib has a narrow therapeutic window, with considerable differences between patients. Dosing based on pharmacokinetics (PK) may help overcome some of those issues. This study aims to evaluate and compare the cost-effectiveness of PK-guided individualized treatment of sunitinib with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972915/ https://www.ncbi.nlm.nih.gov/pubmed/35371296 http://dx.doi.org/10.1177/17588359221085212 |
_version_ | 1784679950334296064 |
---|---|
author | Chen, Tingting Chen, Jiahe Chen, Chaoxin Guo, Jianming He, Xin Zheng, Song Liu, Maobai Zheng, Bin |
author_facet | Chen, Tingting Chen, Jiahe Chen, Chaoxin Guo, Jianming He, Xin Zheng, Song Liu, Maobai Zheng, Bin |
author_sort | Chen, Tingting |
collection | PubMed |
description | BACKGROUND: Sunitinib has a narrow therapeutic window, with considerable differences between patients. Dosing based on pharmacokinetics (PK) may help overcome some of those issues. This study aims to evaluate and compare the cost-effectiveness of PK-guided individualized treatment of sunitinib with its standard dose in patients with metastatic renal cell carcinoma (mRCC). METHODS: A comprehensive literature search was performed, and relevant values were used to provide information for the decision analysis model. Utility data were derived from published studies, and costs were obtained from the perspective of payers in China and the United States. A Markov model was established to evaluate the associated costs and health outcomes for patients. The primary outputs of the model included lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). One-way and probability sensitivity analyses were conducted to evaluate the potential uncertainties of parameters. RESULTS: Cost-effective analysis showed that the QALY of the PK-guided group increased by 0.83 compared with that in the standard dose group. From the perspective of both countries’ health systems, the cost of PK-guided dose was lower than that of standard dose. Hence, PK-guided treatment was the dominant strategy. One-way and probability sensitivity analyses confirmed the reliability of these results. CONCLUSION: On the basis of currently available data, PK-guided sunitinib treatment may be a safe, effective, and economical intervention for patients with mRCC. |
format | Online Article Text |
id | pubmed-8972915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89729152022-04-02 Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma Chen, Tingting Chen, Jiahe Chen, Chaoxin Guo, Jianming He, Xin Zheng, Song Liu, Maobai Zheng, Bin Ther Adv Med Oncol Original Research BACKGROUND: Sunitinib has a narrow therapeutic window, with considerable differences between patients. Dosing based on pharmacokinetics (PK) may help overcome some of those issues. This study aims to evaluate and compare the cost-effectiveness of PK-guided individualized treatment of sunitinib with its standard dose in patients with metastatic renal cell carcinoma (mRCC). METHODS: A comprehensive literature search was performed, and relevant values were used to provide information for the decision analysis model. Utility data were derived from published studies, and costs were obtained from the perspective of payers in China and the United States. A Markov model was established to evaluate the associated costs and health outcomes for patients. The primary outputs of the model included lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). One-way and probability sensitivity analyses were conducted to evaluate the potential uncertainties of parameters. RESULTS: Cost-effective analysis showed that the QALY of the PK-guided group increased by 0.83 compared with that in the standard dose group. From the perspective of both countries’ health systems, the cost of PK-guided dose was lower than that of standard dose. Hence, PK-guided treatment was the dominant strategy. One-way and probability sensitivity analyses confirmed the reliability of these results. CONCLUSION: On the basis of currently available data, PK-guided sunitinib treatment may be a safe, effective, and economical intervention for patients with mRCC. SAGE Publications 2022-03-30 /pmc/articles/PMC8972915/ /pubmed/35371296 http://dx.doi.org/10.1177/17588359221085212 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Chen, Tingting Chen, Jiahe Chen, Chaoxin Guo, Jianming He, Xin Zheng, Song Liu, Maobai Zheng, Bin Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title | Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title_full | Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title_fullStr | Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title_full_unstemmed | Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title_short | Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
title_sort | systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972915/ https://www.ncbi.nlm.nih.gov/pubmed/35371296 http://dx.doi.org/10.1177/17588359221085212 |
work_keys_str_mv | AT chentingting systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT chenjiahe systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT chenchaoxin systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT guojianming systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT hexin systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT zhengsong systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT liumaobai systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma AT zhengbin systematicreviewandcosteffectivenessofpharmacokineticallyguidedsunitinibindividualizedtreatmentforpatientswithmetastaticrenalcellcarcinoma |